论文部分内容阅读
目的:观察巨噬细胞移动抑制因子(Macrophage migration Inhibitory Factor,MIF)在多发性骨髓瘤(Multiple Myeloma,MM)患者血浆中的表达及与肿瘤负荷指标包括血β2-微球蛋白(serumβ2 microglobulin,β2-MG)、C-反应蛋白(C-reactive protein,CRP)、乳酸脱氢酶(lactic acid dehydrogenase,LDH)、血清白蛋白(serum albumin,ALB)的相关性。方法:随机选择多发性骨髓瘤患者30例作为观察组,28例健康人为对照组。以ELISA(enzyme-linked immunosorbent assay,ELISA)方法检测两组人群静脉血浆MIF浓度,并检测观察组肿瘤负荷相关指标,分析与MIF相关性。结果:1与对照组MIF检测浓度值比较(2386.76±679.66pg/m L),观察组血浆MIF浓度明显高表达(8153.18.16±2043.73 pg/ml),两组比较,具有统计学意义,P<0.05。2MIF与β2-MG、CRP呈正相关(p=0.031、0.021;r=0.712、0.46);与ALB呈负相关(p=0.047;-0.215);与LDH无明显相关性(P=0.679)。结论:MIF检测在多发性骨髓瘤的临床诊断、分期和判断预后有重要参考价值。
OBJECTIVE: To observe the expression of macrophage migration inhibitory factor (MIF) in the plasma of patients with multiple myeloma (MM) and to evaluate the relationship between the tumor burden and serum β2 microglobulin (β2 -MG), C-reactive protein (CRP), lactic acid dehydrogenase (LDH) and serum albumin (ALB). Methods: Thirty patients with multiple myeloma were randomly selected as observation group and 28 healthy people as control group. The concentrations of MIF in venous plasma of two groups were detected by enzyme-linked immunosorbent assay (ELISA) and the tumor burden in the observation group was detected, and the correlation with MIF was analyzed. Results: Compared with control group (2386.76 ± 679.66pg / m L), the MIF concentration in the observation group was significantly higher than that in the control group (8153.18.16 ± 2043.73 pg / ml). There was significant difference between the two groups <0.05.2 There was a positive correlation between MIF and β2-MG and CRP (p = 0.031,0.021; r = 0.712,0.46), negative correlation with ALB (p = 0.047 and -0.215) ). Conclusion: The MIF detection in multiple myeloma clinical diagnosis, stage and prognosis have important reference value.